Exploring the divergence in perspectives on clinical trial operations in South Korea during the COVID-19 pandemic: a comparison of a trial site and sponsors.

Front Med (Lausanne)

CHA Global Clinical Trials Center, CHA Bundang Medical Center, CHA University, Seongnam, Republic of Korea.

Published: March 2024

AI Article Synopsis

  • Decentralized clinical trials (DCTs) emerged during the COVID-19 pandemic, highlighting differing perspectives between clinical trial sites and sponsors in South Korea regarding their implementation and challenges.
  • Both groups reported difficulties during the pandemic, with trial site personnel often relying on their own solutions, while sponsors emphasized the importance of collaboration with sites.
  • Effective communication and cooperation between sponsors and sites are essential for overcoming challenges, and government support is needed to facilitate the successful adoption of DCTs through regulatory changes.*

Article Abstract

Introduction: During the COVID-19 pandemic, novel clinical trial methods known as decentralized clinical trials (DCTs) were rapidly introduced. The attitude toward operating clinical trials and perspectives on DCTs may differ between clinical trial sites and sponsors. The impact of the COVID-19 pandemic on clinical trials was investigated for a society of sponsors and a trial site in South Korea.

Methods: The current difficulties and future perspectives on clinical trials were assessed and compared between the site and sponsors.

Results: Both the site and sponsors reported on their experiences with the challenges of conducting clinical trials during the pandemic era. While 64% of personnel from the site judged that the difficulties were solved by their own solutions, 67.6% of personnel from sponsors considered cooperation with trial sites as a key solution to overcome the difficulties. While half of the personnel from the site were skeptical of the changes in trial operation methods, the sponsors expected the institutionalization of DCT elements.

Conclusion: In conclusion, with varying attitudes, sponsors and sites attempted to overcome the challenges of conducting clinical trials during the pandemic era. To conduct clinical trials effectively, both sponsors and sites must work closely together to find solutions with efficient communication. For the successful implementation of new tools such as DCTs, the government needs to solicit support from sponsors and sites and change regulations.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10950924PMC
http://dx.doi.org/10.3389/fmed.2024.1342184DOI Listing

Publication Analysis

Top Keywords

clinical trials
28
clinical trial
12
covid-19 pandemic
12
sponsors sites
12
clinical
10
sponsors
9
perspectives clinical
8
trial site
8
site sponsors
8
trial sites
8

Similar Publications

Introduction: In inflammatory bowel disease (IBD), the number of eosinophils increases in the lamina propria of the intestinal tract, but their specific patho-mechanistic role remains unclear. Elevated blood eosinophil counts in active IBD suggest their potential as biomarkers for predicting response to biologic therapies. This study evaluates blood eosinophil count trends and their predictive value for clinical response and endoscopic improvement in patients with IBD receiving ustekinumab or adalimumab induction therapy.

View Article and Find Full Text PDF

Background: Improving adherence to pre-exposure prophylaxis (PrEP) via digital health interventions (DHIs) for young sexual and gender minority men who have sex with men (YSGMMSM) is promising for reducing the HIV burden. Measuring and achieving effective engagement (sufficient to solicit PrEP adherence) in YSGMMSM is challenging.

Objective: This study is a secondary analysis of the primary efficacy randomized controlled trial (RCT) of Prepared, Protected, Empowered (P3), a digital PrEP adherence intervention that used causal mediation to quantify whether and to what extent intrapersonal behavioral, mental health, and sociodemographic measures were related to effective engagement for PrEP adherence in YSGMMSM.

View Article and Find Full Text PDF

Acute Pancreatitis: An Update of Evidence-Based Management and Recent Trends in Treatment Strategies.

United European Gastroenterol J

January 2025

Department of Gastroenterology and Hepatology, Amsterdam Gastroenterology Endocrinology Metabolism, Amsterdam UMC, Location University of Amsterdam, Amsterdam, the Netherlands.

Acute pancreatitis is a common gastrointestinal disease leading to hospitalisation. Recent advancements in its management have primarily focussed on the development of early phase medical interventions targeting inflammatory pathways, optimisation of supportive treatment (including fluid resuscitation, pain management and nutritional management), appropriate use of antibiotics, implementation of minimally invasive interventions for infected necrosis, and the necessity of follow-up for long-term complications. These advancements have significantly improved personalised management and overall outcomes of acute pancreatitis.

View Article and Find Full Text PDF

Importance: The open-label randomized phase 2 LACOG0415 trial evaluated 3 treatment strategies for patients with advanced castration-sensitive prostate cancer (CSPC): androgen deprivation therapy (ADT) plus abiraterone acetate and prednisone (AAP), apalutamide (APA) alone, or APA plus AAP.

Objective: To investigate the association of ADT plus AAP, APA alone, or APA plus AAP with health-related quality of life (HRQOL) in patients with advanced CSPC in the LACOG0415 trial.

Design, Setting, And Participants: The LACOG0415 randomized clinical trial comprised 128 patients with advanced CSPC who were randomized (1:1:1) to 1 of 3 treatment arms from October 16, 2017, to April 23, 2019.

View Article and Find Full Text PDF

Antiviral Medications for Treatment of Nonsevere Influenza: A Systematic Review and Network Meta-Analysis.

JAMA Intern Med

January 2025

Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada.

Importance: The optimal antiviral drug for treatment of nonsevere influenza remains unclear.

Objective: To compare effects of antiviral drugs for treating nonsevere influenza.

Data Sources: MEDLINE, Embase, CENTRAL, CINAHL, Global Health, Epistemonikos, and ClinicalTrials.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!